- Home
- ESCA vs INZY Comparison
ESCA vs INZY Comparison
Compare ESCA & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESCA
- INZY
- Stock Information
- Founded
- ESCA 1922
- INZY 2015
- Country
- ESCA United States
- INZY United States
- Employees
- ESCA N/A
- INZY N/A
- Industry
- ESCA Recreational Games/Products/Toys
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- ESCA Consumer Discretionary
- INZY Health Care
- Exchange
- ESCA Nasdaq
- INZY Nasdaq
- Market Cap
- ESCA 198.2M
- INZY 188.2M
- IPO Year
- ESCA N/A
- INZY 2020
- Fundamental
- Price
- ESCA $14.99
- INZY $1.36
- Analyst Decision
- ESCA
- INZY Strong Buy
- Analyst Count
- ESCA 0
- INZY 8
- Target Price
- ESCA N/A
- INZY $17.75
- AVG Volume (30 Days)
- ESCA 18.4K
- INZY 1.0M
- Earning Date
- ESCA 03-31-2025
- INZY 03-11-2025
- Dividend Yield
- ESCA 4.04%
- INZY N/A
- EPS Growth
- ESCA 35.81
- INZY N/A
- EPS
- ESCA 0.94
- INZY N/A
- Revenue
- ESCA $253,074,000.00
- INZY N/A
- Revenue This Year
- ESCA N/A
- INZY N/A
- Revenue Next Year
- ESCA N/A
- INZY N/A
- P/E Ratio
- ESCA $15.52
- INZY N/A
- Revenue Growth
- ESCA N/A
- INZY N/A
- 52 Week Low
- ESCA $12.34
- INZY $1.24
- 52 Week High
- ESCA $17.36
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- ESCA 49.82
- INZY 29.28
- Support Level
- ESCA $14.31
- INZY $1.35
- Resistance Level
- ESCA $16.19
- INZY $1.62
- Average True Range (ATR)
- ESCA 0.53
- INZY 0.13
- MACD
- ESCA -0.03
- INZY 0.04
- Stochastic Oscillator
- ESCA 36.17
- INZY 32.89
About ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.